LIVIVO - Search results -

Search results

Result 1 - 10 of total 21

Search options

Article ; Online: Multi-institutional outcomes after femoropopliteal bypass in octogenarians.

Kim, Young / Cho, Bennet S / DeCarlo, Charles S / Latz, Christopher A / Majumdar, Monica / Zacharias, Nikolaos / Mohapatra, Abhisekh / Dua, Anahita

Vascular

2022 Volume 32, Issue 1, Page(s) 84–90

Abstract: Objectives: Open lower extremity revascularization is controversial among octogenarians; however, the indications for surgical bypass are higher in the elderly population. The aim of the study was to compare postoperative outcomes between octogenarians ... ...

Abstract	Objectives: Open lower extremity revascularization is controversial among octogenarians; however, the indications for surgical bypass are higher in the elderly population. The aim of the study was to compare postoperative outcomes between octogenarians and non-octogenarians following femoropopliteal bypass surgery. Methods: Our regional, multi-institutional database was queried for femoropopliteal bypass procedures performed between 1995 and 2020. Electronic medical records were individually reviewed for operative and postoperative data. Univariable and multivariable logistic regression were utilized to determine predictors of postoperative outcomes. Results: Among 1315 patients who underwent femoropopliteal bypass, 234 (17.8%) were octogenarians. Octogenarians more frequently underwent bypass for lower extremity tissue loss (48.7% vs 30.2%), whereas claudication was more common among non-octogenarians (24.0% vs 9.8%) ( Conclusions: Octogenarians undergoing bypass femoropopliteal bypass surgery have considerably worse postoperative outcomes, compared with non-octogenarians. These data may help inform elderly patients prior to undergoing open lower extremity revascularization.
MeSH term(s)	Aged, 80 and over ; Humans ; Aged ; Octogenarians ; Postoperative Complications/etiology ; Retrospective Studies ; Risk Factors ; Blood Vessel Prosthesis Implantation/adverse effects ; Treatment Outcome
Language	English
Publishing date	2022-09-05
Publishing country	England
Document type	Journal Article
ZDB-ID	2137151-9
ISSN	1708-539X ; 1708-5381
ISSN (online)	1708-539X
ISSN	1708-5381
DOI	10.1177/17085381221125953
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4277: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 590: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Structurally‐engineered fatty acid 1024 (SEFA‐1024) improves diet‐induced obesity, insulin resistance, and fatty liver disease

Secor, Jordon D. / Cho, Bennet S. / Yu, Lumeng J. / Pan, Amy / Ko, Victoria H. / Dao, Duy T. / Feigh, Michael / Anez‐Bustillos, Lorenzo / Fell, Gillian L. / Fraser, David A. / Gura, Kathleen M. / Puder, Mark

Lipids. 2022 July, v. 57, no. 4-5

2022

Abstract: Obesity is a global epidemic that drives morbidity and mortality through cardiovascular disease, diabetes, and non‐alcoholic fatty liver disease (NAFLD). No definitive therapy has been approved to improve glycemic control and treat NAFLD in obese ... ...

Abstract	Obesity is a global epidemic that drives morbidity and mortality through cardiovascular disease, diabetes, and non‐alcoholic fatty liver disease (NAFLD). No definitive therapy has been approved to improve glycemic control and treat NAFLD in obese patients. Here, we investigated a semi‐synthetic, long chain, structurally‐engineered fatty acid‐1024 (SEFA‐1024), as a treatment for obesity‐induced hyperglycemia, insulin‐resistance, and fatty liver disease in rodent models. A single dose of SEFA‐1024 was administered to evaluate glucose tolerance and active glucagon‐like peptide 1 (GLP‐1) in lean rats in the presence and absence of a DPP‐4 inhibitor. The effects of SEFA‐1024 on weight loss and glycemic control were assessed in genetic (ob/ob) and environmental (high‐fat diet) murine models of obesity. Liver histology, serum liver enzymes, liver lipidomics, and hepatic gene expression were also assessed in the high‐fat diet murine model. SEFA‐1024 reversed obesity‐associated insulin resistance and improved glycemic control. SEFA‐1024 increased active GLP‐1. In a long‐term model of diet‐induced obesity, SEFA‐1024 reversed excessive weight gain, hepatic steatosis, elevated liver enzymes, hepatic lipotoxicity, and promoted fatty acid metabolism. SEFA‐1024 is an enterohepatic‐targeted, eicosapentaenoic acid derivative that reverses obesity‐induced dysregulated glucose metabolism and hepatic lipotoxicity in genetic and dietary rodent models of obesity. The mechanism by which SEFA‐1024 works may include increasing aGLP‐1, promoting fatty acid oxidation, and inhibiting hepatic triglyceride formation. SEFA‐1024 may serve as a potential treatment for obesity‐related diabetes and NAFLD.
Keywords	animal models ; beta oxidation ; blood serum ; cardiovascular diseases ; diabetes ; eicosapentaenoic acid ; fatty acid metabolism ; fatty liver ; gene expression ; glucagon-like peptide 1 ; glucose ; glucose tolerance ; glycemic control ; high fat diet ; histology ; hyperglycemia ; insulin resistance ; lipidomics ; lipotoxicity ; liver ; mice ; morbidity ; mortality ; obesity ; therapeutics ; triacylglycerols ; weight gain ; weight loss
Language	English
Dates of publication	2022-07
Size	p. 241-255.
Publishing place	John Wiley & Sons, Inc.
Document type	Article
Note	JOURNAL ARTICLE
ZDB-ID	241539-2
ISSN	1558-9307 ; 0024-4201
ISSN (online)	1558-9307
ISSN	0024-4201
DOI	10.1002/lipd.12351
Database	NAL-Catalogue (AGRICOLA)

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 645: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: A medium-chain fatty acid analogue prevents hepatosteatosis and decreases inflammatory lipid metabolites in a murine model of parenteral nutrition-induced hepatosteatosis.

Cho, Bennet S / Fligor, Scott C / Fell, Gillian L / Secor, Jordan D / Tsikis, Savas T / Pan, Amy / Yu, Lumeng J / Ko, Victoria H / Dao, Duy T / Anez-Bustillos, Lorenzo / Hirsch, Thomas I / Lund, Jenny / Rustan, Arild C / Fraser, David A / Gura, Kathleen M / Puder, Mark

PloS one

2023 Volume 18, Issue 12, Page(s) e0295244

Abstract: Background: Parenteral (intravenous) nutrition is lifesaving for patients with intestinal failure, but long-term use of parenteral nutrition often leads to liver disease. SEFA-6179 is a synthetic medium-chain fatty acid analogue designed to target ... ...

Abstract	Background: Parenteral (intravenous) nutrition is lifesaving for patients with intestinal failure, but long-term use of parenteral nutrition often leads to liver disease. SEFA-6179 is a synthetic medium-chain fatty acid analogue designed to target multiple fatty acid receptors regulating metabolic and inflammatory pathways. We hypothesized that SEFA-6179 would prevent hepatosteatosis and lipotoxicity in a murine model of parenteral nutrition-induced hepatosteatosis. Methods: Two in vivo experiments were conducted. In the first experiment, six-week-old male mice were provided an ad lib fat-free high carbohydrate diet (HCD) for 19 days with orogastric gavage of either fish oil, medium-chain triglycerides, or SEFA-6179 at a low (0.3mmol/kg) or high dose (0.6mmol/kg). In the second experiment, six-week-old mice were provided an ad lib fat-free high carbohydrate diet for 19 days with every other day tail vein injection of saline, soybean oil lipid emulsion, or fish oil lipid emulsion. Mice then received every other day orogastric gavage of medium-chain triglyceride vehicle or SEFA-6179 (0.6mmol/kg). Hepatosteatosis was assessed by a blinded pathologist using an established rodent steatosis score. Hepatic lipid metabolites were assessed using ultra-high-performance liquid chromatography-mass spectrometry. Effects of SEFA-6179 on fatty acid oxidation, lipogenesis, and fatty acid uptake in human liver cells were assessed in vitro. Results: In the first experiment, mice receiving the HCD with either saline or medium-chain triglyceride treatment developed macrovesicular steatosis, while mice receiving fish oil or SEFA-6179 retained normal liver histology. In the second experiment, mice receiving a high carbohydrate diet with intravenous saline or soybean oil lipid emulsion, along with medium chain triglyceride vehicle treatment, developed macrovescular steatosis. Treatment with SEFA-6179 prevented steatosis. In each experiment, SEFA-6179 treatment decreased arachidonic acid metabolites as well as key molecules (diacylglycerol, ceramides) involved in lipotoxicity. SEFA-6179 increased both β- and complete fatty oxidation in human liver cells, while having no impact on lipogenesis or fatty acid uptake. Conclusions: SEFA-6179 treatment prevented hepatosteatosis and decreased toxic lipid metabolites in a murine model of parenteral nutrition-induced hepatosteatosis. An increase in both β- and complete hepatic fatty acid oxidation may underlie the reduction in steatosis.
MeSH term(s)	Humans ; Male ; Animals ; Mice ; Soybean Oil ; Emulsions ; Disease Models, Animal ; Parenteral Nutrition/adverse effects ; Parenteral Nutrition/methods ; Fatty Acids/metabolism ; Fish Oils ; Fatty Liver/pathology ; Liver/metabolism ; Triglycerides/metabolism ; Carbohydrates ; Fat Emulsions, Intravenous
Chemical Substances	Soybean Oil (8001-22-7) ; Emulsions ; Fatty Acids ; Fish Oils ; Triglycerides ; Carbohydrates ; Fat Emulsions, Intravenous
Language	English
Publishing date	2023-12-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0295244
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease.

Secor, Jordon D / Cho, Bennet S / Yu, Lumeng J / Pan, Amy / Ko, Victoria H / Dao, Duy T / Feigh, Michael / Anez-Bustillos, Lorenzo / Fell, Gillian L / Fraser, David A / Gura, Kathleen M / Puder, Mark

Lipids

2022 Volume 57, Issue 4-5, Page(s) 241–255

Abstract: Obesity is a global epidemic that drives morbidity and mortality through cardiovascular disease, diabetes, and non-alcoholic fatty liver disease (NAFLD). No definitive therapy has been approved to improve glycemic control and treat NAFLD in obese ... ...

Abstract	Obesity is a global epidemic that drives morbidity and mortality through cardiovascular disease, diabetes, and non-alcoholic fatty liver disease (NAFLD). No definitive therapy has been approved to improve glycemic control and treat NAFLD in obese patients. Here, we investigated a semi-synthetic, long chain, structurally-engineered fatty acid-1024 (SEFA-1024), as a treatment for obesity-induced hyperglycemia, insulin-resistance, and fatty liver disease in rodent models. A single dose of SEFA-1024 was administered to evaluate glucose tolerance and active glucagon-like peptide 1 (GLP-1) in lean rats in the presence and absence of a DPP-4 inhibitor. The effects of SEFA-1024 on weight loss and glycemic control were assessed in genetic (ob/ob) and environmental (high-fat diet) murine models of obesity. Liver histology, serum liver enzymes, liver lipidomics, and hepatic gene expression were also assessed in the high-fat diet murine model. SEFA-1024 reversed obesity-associated insulin resistance and improved glycemic control. SEFA-1024 increased active GLP-1. In a long-term model of diet-induced obesity, SEFA-1024 reversed excessive weight gain, hepatic steatosis, elevated liver enzymes, hepatic lipotoxicity, and promoted fatty acid metabolism. SEFA-1024 is an enterohepatic-targeted, eicosapentaenoic acid derivative that reverses obesity-induced dysregulated glucose metabolism and hepatic lipotoxicity in genetic and dietary rodent models of obesity. The mechanism by which SEFA-1024 works may include increasing aGLP-1, promoting fatty acid oxidation, and inhibiting hepatic triglyceride formation. SEFA-1024 may serve as a potential treatment for obesity-related diabetes and NAFLD.
MeSH term(s)	Animals ; Diabetes Mellitus/metabolism ; Diabetes Mellitus/pathology ; Diet, High-Fat/adverse effects ; Fatty Acids/metabolism ; Glucagon-Like Peptide 1/metabolism ; Glucagon-Like Peptide 1/pharmacology ; Glucagon-Like Peptide 1/therapeutic use ; Insulin Resistance ; Lipid Metabolism ; Liver/metabolism ; Mice ; Mice, Inbred C57BL ; Non-alcoholic Fatty Liver Disease/drug therapy ; Non-alcoholic Fatty Liver Disease/etiology ; Obesity/genetics ; Rats
Chemical Substances	Fatty Acids ; Glucagon-Like Peptide 1 (89750-14-1)
Language	English
Publishing date	2022-07-01
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	241539-2
ISSN	1558-9307 ; 0024-4201
ISSN (online)	1558-9307
ISSN	0024-4201
DOI	10.1002/lipd.12351
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 645: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Incidence and development of cholestasis in surgical neonates receiving an intravenous mixed-oil lipid emulsion.

Yu, Lumeng J / Anez-Bustillos, Lorenzo / Mitchell, Paul D / Ko, Victoria H / Secor, Jordan D / Hurley, Alexis P / Dao, Duy T / Fligor, Scott C / Cho, Bennet S / Tsikis, Savas T / Gura, Kathleen M / Puder, Mark

JPEN. Journal of parenteral and enteral nutrition

2022 Volume 47, Issue 1, Page(s) 30–40

Abstract: Background: Intestinal failure-associated liver disease (IFALD), initially manifesting as cholestasis, is a complication in neonates receiving parenteral nutrition (PN). Soybean oil lipid emulsion (SOLE), though implicated in IFALD, was the only US Food ...

Abstract	Background: Intestinal failure-associated liver disease (IFALD), initially manifesting as cholestasis, is a complication in neonates receiving parenteral nutrition (PN). Soybean oil lipid emulsion (SOLE), though implicated in IFALD, was the only US Food and Drug Administration (FDA)-approved initial intravenous lipid emulsion (ILE) for infants and children in the United States. A mixed-oil lipid emulsion (MOLE) gained popularity in patients at risk for IFALD and was recently FDA approved as an initial ILE in children. Given the presence of soybean oil in MOLE, we hypothesized that MOLE would not be effective at preventing cholestasis in surgical neonates. Methods: Neonates with gastrointestinal surgical conditions necessitating PN for ≥14 days and receiving MOLE (SMOFlipid) from July 2016 to July 2019 were analyzed retrospectively. Unpaired and pair-matched historical surgical neonates treated with SOLE (Intralipid) served as controls. The primary outcome measure was development of cholestasis (direct bilirubin ≥2 mg/dl). Results: Overall, 63% (10 of 16) of MOLE patients and 22% (30 of 136) of SOLE patients developed cholestasis after ≥14 days of therapy (P = 0.005). The latency to developing cholestasis was significantly shorter in MOLE patients compared with SOLE patients. Conclusion: In surgical neonates, MOLE may not prevent cholestasis and should not be considered hepatoprotective. Regardless of ILE source, all surgical neonates should be closely monitored for development of IFALD. To date, there is still no ILE able to prevent IFALD.
MeSH term(s)	Infant ; Infant, Newborn ; Child ; Humans ; Fat Emulsions, Intravenous ; Soybean Oil ; Incidence ; Retrospective Studies ; Cholestasis/etiology ; Cholestasis/therapy ; Liver Diseases/therapy ; Intestinal Diseases/therapy ; Fish Oils/therapeutic use ; Liver Failure/complications
Chemical Substances	Fat Emulsions, Intravenous ; Soybean Oil (8001-22-7) ; Fish Oils
Language	English
Publishing date	2022-11-15
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	800861-9
ISSN	1941-2444 ; 0148-6071
ISSN (online)	1941-2444
ISSN	0148-6071
DOI	10.1002/jpen.2458
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1524: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Effects of systemic anticoagulation in a murine model of compensatory lung growth.

Yu, Lumeng J / Ko, Victoria H / Tsikis, Savas T / Dao, Duy T / Secor, Jordan D / Pan, Amy / Cho, Bennet S / Michell, Paul D / Fligor, Scott C / Kishikawa, Hiroko / Puder, Mark

Pediatric research

2022 Volume 93, Issue 7, Page(s) 1846–1855

Abstract: Background: Neonates with congenital diaphragmatic hernia (CDH) suffer from pulmonary hypoplasia (PH) and may require extracorporeal membrane oxygenation (ECMO) and anticoagulation, often with unfractionated heparin (UFH). UFH interacts with vascular ... ...

Abstract	Background: Neonates with congenital diaphragmatic hernia (CDH) suffer from pulmonary hypoplasia (PH) and may require extracorporeal membrane oxygenation (ECMO) and anticoagulation, often with unfractionated heparin (UFH). UFH interacts with vascular endothelial growth factor (VEGF), a factor important in lung development. We investigated the effects of UFH, low molecular weight heparin (LMWH), and bivalirudin (BV) on a murine model of compensatory lung growth (CLG). Methods: Proliferation and apoptosis were assessed in microvascular lung endothelial cells (HMVEC-L) treated with anticoagulants. Eight-week-old C57Bl/6J mice underwent left pneumonectomy and anticoagulation with low- or high-dose UFH, LMWH, BV, or saline control. Lung volume, pulmonary function tests, morphometrics, treadmill exercise tolerance, and pulmonary protein expression were examined. Results: UFH and LMWH inhibited HMVEC-L proliferation. BV promoted proliferation and decreased apoptosis. UFH and LMWH-treated mice had reduced lung volume, total lung capacity, alveolar volume, and septal surface area compared to controls, while BV did not affect these measures. UFH and LMWH-treated mice had lower exercise tolerance compared to controls. Conclusions: UFH and LMWH impair pulmonary growth, alveolarization, and exercise tolerance, while BV does not. Alternative anticoagulants to heparin may be considered to improve functional outcomes for neonates with CDH and pulmonary hypoplasia. Impact: Unfractionated heparin and low molecular weight heparin may modify compensatory lung growth by reducing microvascular lung endothelial cell proliferation and affecting pulmonary angiogenic signaling. Functional effects of unfractionated heparin and low molecular weight heparin on murine compensatory lung growth include reduction in exercise tolerance. Bivalirudin, a direct thrombin inhibitor, may increase microvascular lung endothelial cell proliferation and preserves lung volume, alveolarization, and exercise tolerance in a murine compensatory lung growth model. Anticoagulants alternative to heparin should be further investigated for use in neonates with pulmonary hypoplastic diseases to optimize lung growth and development and improve outcomes.
MeSH term(s)	Animals ; Mice ; Heparin/pharmacology ; Heparin, Low-Molecular-Weight/pharmacology ; Vascular Endothelial Growth Factor A ; Endothelial Cells ; Disease Models, Animal ; Anticoagulants/pharmacology ; Lung ; Hernias, Diaphragmatic, Congenital
Chemical Substances	Heparin (9005-49-6) ; Heparin, Low-Molecular-Weight ; Vascular Endothelial Growth Factor A ; Anticoagulants
Language	English
Publishing date	2022-10-04
Publishing country	United States
Document type	Journal Article
ZDB-ID	4411-8
ISSN	1530-0447 ; 0031-3998
ISSN (online)	1530-0447
ISSN	0031-3998
DOI	10.1038/s41390-022-02323-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 564: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 373: Show issues

Order via subito

Details ▾

Article ; Online: Investigation of the mechanisms of VEGF-mediated compensatory lung growth: the role of the VEGF heparin-binding domain.

Yu, Lumeng J / Ko, Victoria H / Dao, Duy T / Secor, Jordan D / Pan, Amy / Cho, Bennet S / Mitchell, Paul D / Kishikawa, Hiroko / Bielenberg, Diane R / Puder, Mark

Scientific reports

2021 Volume 11, Issue 1, Page(s) 11827

Abstract: Morbidity and mortality for neonates with congenital diaphragmatic hernia-associated pulmonary hypoplasia remains high. These patients may be deficient in vascular endothelial growth factor (VEGF). Our lab previously established that exogenous VEGF164 ... ...

Abstract	Morbidity and mortality for neonates with congenital diaphragmatic hernia-associated pulmonary hypoplasia remains high. These patients may be deficient in vascular endothelial growth factor (VEGF). Our lab previously established that exogenous VEGF164 accelerates compensatory lung growth (CLG) after left pneumonectomy in a murine model. We aimed to further investigate VEGF-mediated CLG by examining the role of the heparin-binding domain (HBD). Eight-week-old, male, C57BL/6J mice underwent left pneumonectomy, followed by post-operative and daily intraperitoneal injections of equimolar VEGF164 or VEGF120, which lacks the HBD. Isovolumetric saline was used as a control. VEGF164 significantly increased lung volume, total lung capacity, and alveolarization, while VEGF120 did not. Treadmill exercise tolerance testing (TETT) demonstrated improved functional outcomes post-pneumonectomy with VEGF164 treatment. In lung protein analysis, VEGF treatment modulated downstream angiogenic signaling. Activation of epithelial growth factor receptor and pulmonary cell proliferation was also upregulated. Human microvascular lung endothelial cells (HMVEC-L) treated with VEGF demonstrated decreased potency of VEGFR2 activation with VEGF121 treatment compared to VEGF165 treatment. Taken together, these data indicate that the VEGF HBD contributes to angiogenic and proliferative signaling, is required for accelerated compensatory lung growth, and improves functional outcomes in a murine CLG model.
MeSH term(s)	Animals ; Cell Proliferation ; Drug Design ; Endothelial Cells/metabolism ; Exercise Test ; Hematocrit ; Heparin/chemistry ; Humans ; Lung/metabolism ; Lung/physiology ; Lung/physiopathology ; Male ; Mice ; Mice, Inbred C57BL ; Microcirculation ; Pneumonectomy ; Protein Domains ; Signal Transduction ; Vascular Endothelial Growth Factor A/chemistry ; Vascular Endothelial Growth Factor A/metabolism
Chemical Substances	VEGFA protein, human ; Vascular Endothelial Growth Factor A ; vascular endothelial growth factor A, mouse ; Heparin (9005-49-6)
Language	English
Publishing date	2021-06-04
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-021-91127-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Assessment of Micronutrient Status in Critically Ill Children: Challenges and Opportunities

Dao, Duy T / Anez-Bustillos, Lorenzo / Cho, Bennet S / Li, Zhilling / Puder, Mark / Gura, Kathleen M

Nutrients. 2017 Oct. 28, v. 9, no. 11

2017

Abstract: Micronutrients refer to a group of organic vitamins and inorganic trace elements that serve many functions in metabolism. Assessment of micronutrient status in critically ill children is challenging due to many complicating factors, such as evolving ... ...

Abstract	Micronutrients refer to a group of organic vitamins and inorganic trace elements that serve many functions in metabolism. Assessment of micronutrient status in critically ill children is challenging due to many complicating factors, such as evolving metabolic demands, immature organ function, and varying methods of feeding that affect nutritional dietary intake. Determination of micronutrient status, especially in children, usually relies on a combination of biomarkers, with only a few having been established as a gold standard. Almost all micronutrients display a decrease in their serum levels in critically ill children, resulting in an increased risk of deficiency in this setting. While vitamin D deficiency is a well-known phenomenon in critical illness and can predict a higher need for intensive care, serum concentrations of many trace elements such as iron, zinc, and selenium decrease as a result of tissue redistribution in response to systemic inflammation. Despite a decrease in their levels, supplementation of micronutrients during times of severe illness has not demonstrated clear benefits in either survival advantage or reduction of adverse outcomes. For many micronutrients, the lack of large and randomized studies remains a major hindrance to critically evaluating their status and clinical significance.
Keywords	biomarkers ; blood serum ; children ; disease severity ; food intake ; inflammation ; iron ; metabolism ; selenium ; vitamin D deficiency ; vitamins ; zinc
Language	English
Dates of publication	2017-1028
Publishing place	Multidisciplinary Digital Publishing Institute
Document type	Article
ZDB-ID	2518386-2
ISSN	2072-6643
ISSN	2072-6643
DOI	10.3390/nu9111185
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Article ; Online: Roxadustat (FG-4592) accelerates pulmonary growth, development, and function in a compensatory lung growth model.

Ko, Victoria H / Yu, Lumeng J / Dao, Duy T / Li, Xiaoran / Secor, Jordan D / Anez-Bustillos, Lorenzo / Cho, Bennet S / Pan, Amy / Mitchell, Paul D / Kishikawa, Hiroko / Puder, Mark

Angiogenesis

2020 Volume 23, Issue 4, Page(s) 637–649

Abstract: Children with hypoplastic lung disease associated with congenital diaphragmatic hernia (CDH) continue to suffer significant morbidity and mortality secondary to progressive pulmonary disease. Current management of CDH is primarily supportive and ... ...

Abstract	Children with hypoplastic lung disease associated with congenital diaphragmatic hernia (CDH) continue to suffer significant morbidity and mortality secondary to progressive pulmonary disease. Current management of CDH is primarily supportive and mortality rates of the most severely affected children have remained unchanged in the last few decades. Previous work in our lab has demonstrated the importance of vascular endothelial growth factor (VEGF)-mediated angiogenesis in accelerating compensatory lung growth. In this study, we evaluated the potential for Roxadustat (FG-4592), a prolyl hydroxylase inhibitor known to increase endogenous VEGF, in accelerating compensatory lung growth. Treatment with Roxadustat increased lung volume, total lung capacity, alveolarization, and exercise tolerance compared to controls following left pneumonectomy. However, this effect was likely modulated not only by increased VEGF, but rather also by decreased pigment epithelium-derived factor (PEDF), an anti-angiogenic factor. Furthermore, this mechanism of action may be specific to Roxadustat. Vadadustat (AKB-6548), a structurally similar prolyl hydroxylase inhibitor, did not demonstrate accelerated compensatory lung growth or decreased PEDF expression following left pneumonectomy. Given that Roxadustat is already in Phase III clinical studies for the treatment of chronic kidney disease-associated anemia with minimal side effects, its use for the treatment of pulmonary hypoplasia could potentially proceed expeditiously.
MeSH term(s)	Animals ; Compliance ; Dose-Response Relationship, Drug ; Endothelial Cells/drug effects ; Endothelial Cells/metabolism ; Eye Proteins ; Glycine/administration & dosage ; Glycine/analogs & derivatives ; Glycine/pharmacology ; Isoquinolines/administration & dosage ; Isoquinolines/pharmacology ; Lung/drug effects ; Lung/growth & development ; Lung/physiology ; Lung/surgery ; Male ; Mice, Inbred C57BL ; Models, Biological ; Nerve Growth Factors ; Organ Size/drug effects ; Phosphorylation/drug effects ; Physical Conditioning, Animal ; Picolinic Acids ; Pneumonectomy ; Pulmonary Alveoli/drug effects ; Pulmonary Alveoli/growth & development ; Respiratory Function Tests ; Serpins ; Total Lung Capacity ; Vascular Endothelial Growth Factor A/metabolism ; Vascular Endothelial Growth Factor Receptor-2/metabolism
Chemical Substances	Eye Proteins ; Isoquinolines ; Nerve Growth Factors ; Picolinic Acids ; Serpins ; Vascular Endothelial Growth Factor A ; pigment epithelium-derived factor ; vadadustat ; Vascular Endothelial Growth Factor Receptor-2 (EC 2.7.10.1) ; Glycine (TE7660XO1C) ; roxadustat (X3O30D9YMX)
Language	English
Publishing date	2020-07-14
Publishing country	Germany
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	1484717-6
ISSN	1573-7209 ; 0969-6970
ISSN (online)	1573-7209
ISSN	0969-6970
DOI	10.1007/s10456-020-09735-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5094: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Optimizing Duration of Empiric Management of Suspected Central Line-Associated Bloodstream Infections in Pediatric Patients with Intestinal Failure.

Fell, Gillian L / Cho, Bennet S / Anez-Bustillos, Lorenzo / Dao, Duy T / Baker, Meredith A / Nandivada, Prathima / O'Loughlin, Alison A / Hurley, Alexis P / Mitchell, Paul D / Rangel, Shawn / Gura, Kathleen M / Puder, Mark

The Journal of pediatrics

2020 Volume 227, Page(s) 69–76.e3

Abstract: Objectives: To assess whether a 24-hour length of hospitalization and empiric antibiotic therapy to exclude central line-associated bloodstream infection (CLABSI) in children with intestinal failure is potentially as safe as 48 hours, which is the ... ...

Abstract	Objectives: To assess whether a 24-hour length of hospitalization and empiric antibiotic therapy to exclude central line-associated bloodstream infection (CLABSI) in children with intestinal failure is potentially as safe as 48 hours, which is the duration most commonly used but not evidence based. Study design: A prospective single-institution observational cohort study was conducted among pediatric patients with intestinal failure from July 1, 2015, through June 30, 2018, to identify episodes of suspected CLABSI. The primary end point was time from blood sampling to positive blood culture. Secondary end points included presenting symptoms, laboratory test results, responses to a parent/legal guardian-completed symptom survey, length of inpatient stay, costs, and charges. Results: Seventy-three patients with intestinal failure receiving nutritional support via central venous catheters enrolled; 35 were hospitalized with suspected CLABSI at least once during the study. There were 49 positive blood cultures confirming CLABSI in 128 episodes (38%). The median time from blood sampling to positive culture was 11.1 hours. The probability of a blood culture becoming positive after 24 hours was 2.3%. Elevated C-reactive protein and neutrophil predominance in white blood cell count were associated with positive blood cultures. Estimated cost savings by transitioning from a 48-hour to a 24-hour admission to rule-out CLABSI was $4639 per admission. Conclusions: A 24-hour duration of empiric management to exclude CLABSI may be appropriate for patients with negative blood cultures and no clinically concerning signs. A multi-institutional study would more robustly differentiate patients safe for discharge after 24 hours from those who warrant longer empiric treatment.
MeSH term(s)	Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/adverse effects ; C-Reactive Protein/analysis ; Case-Control Studies ; Catheter-Related Infections/blood ; Catheter-Related Infections/diagnosis ; Catheter-Related Infections/economics ; Catheter-Related Infections/prevention & control ; Catheterization, Central Venous/adverse effects ; Catheterization, Central Venous/instrumentation ; Catheters, Indwelling/microbiology ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Intestinal Diseases/economics ; Intestinal Diseases/therapy ; Length of Stay/economics ; Length of Stay/statistics & numerical data ; Male ; Parenteral Nutrition/adverse effects ; Parenteral Nutrition/methods ; Prospective Studies ; Surveys and Questionnaires ; Time Factors
Chemical Substances	Anti-Bacterial Agents ; C-Reactive Protein (9007-41-4)
Language	English
Publishing date	2020-07-17
Publishing country	United States
Document type	Journal Article ; Observational Study ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	3102-1
ISSN	1097-6833 ; 0022-3476
ISSN (online)	1097-6833
ISSN	0022-3476
DOI	10.1016/j.jpeds.2020.07.044
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Um IV Zs.116: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito